DCI Seminar Series (4.22.15)

March 10, 2015
By: Karen E. Butler, Director of Communications, DCI

 Gary Johnson, PhDPresented by the DCI Tumor Biology Program, the April DCI Seminar Series will feature Gary Johnson, PhD, Kenan Distinguished Professor and Chair, Department of Pharmacology, UNC School of Medicine. The lecture, “Therapeutic Implications of Kinome Resiliency To Targeted Kinase Inhibitors” will be held from 8:10 a.m. to 9 a.m. in Duke South Amphitheater, Room 0916, on Wednesday, April 22. The lecture will be preceded by a hematology-oncology fellowship presentation from 7:30 a.m. to 8 a.m. DCI members are encouraged to attend.

Johnson is chair of the Department of Pharmacology and as a member of the Lineberger Comprehensive Cancer Center, he serves as the co-director of the Program in Molecular Therapeutics (with Ned Sharpless) and a member of the Program Planning Committee. He is also director of the new Human Genome RNAi Screening Facility that provides automated genome-wide RNAi screens for UNC investigators. Johnson has served on many NIH committees, including the Board of Counselors for the NIDDK, NIGMS Council and chaired many special reviews including the NIGMS Pharmacogenetics Review Committee and served on the NIGMS Glue Grant Review Panel. He has also served on the scientific advisory boards of two publicly traded biotechnology companies. As a basic scientist his research interests include small molecule and RNAi screening for targeting proteins functioning as hubs in signaling networks, high-throughput proteomics using mass spectrometry to define the activity of the kinome in cancer cells (a relatively new research focus for his laboratory), animal models of disease including the epithelial-mesenchymal transition (EMT), metastasis and stem cell biology.

The DCI Seminar Series is held during the Hematology Oncology Grand Rounds, usually on the fourth Wednesday of each month. For more information, contact Erin Carr at 919.681.8148.

Circle photo: René Bernards, PhD, professor of Molecular Carcinogenesis, Netherlands Cancer Institute, poses with Sandeep Dave, MD, MS, associate professor, Division of Oncology, Duke Department of Medicine. Bernards was the featured guest speaker at the DCI Seminar Series held March 25. He spoke on “Synthetic Lethal Drug Combinations For the Treatment of Cancer.”